Ghisallo Capital Management LLC Purchases Shares of 921,587 InspireMD, Inc. $NSPR

Ghisallo Capital Management LLC purchased a new stake in InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 921,587 shares of the company’s stock, valued at approximately $2,221,000.

A number of other institutional investors have also made changes to their positions in the business. Creative Planning acquired a new position in shares of InspireMD during the 2nd quarter worth about $44,000. Uniting Wealth Partners LLC acquired a new stake in InspireMD in the 3rd quarter valued at approximately $51,000. Vestia Personal Wealth Advisors grew its holdings in InspireMD by 135.7% in the 3rd quarter. Vestia Personal Wealth Advisors now owns 42,425 shares of the company’s stock valued at $102,000 after buying an additional 24,425 shares during the last quarter. Raymond James Financial Inc. increased its position in InspireMD by 28.9% in the 2nd quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock worth $101,000 after buying an additional 10,000 shares during the period. Finally, Courier Capital LLC increased its position in InspireMD by 83.3% in the 3rd quarter. Courier Capital LLC now owns 55,000 shares of the company’s stock worth $133,000 after buying an additional 25,000 shares during the period. 44.78% of the stock is currently owned by institutional investors.

InspireMD Stock Performance

NSPR opened at $1.65 on Friday. The stock’s 50 day simple moving average is $1.70 and its 200-day simple moving average is $2.01. The stock has a market cap of $69.91 million, a PE ratio of -2.20 and a beta of 0.87. InspireMD, Inc. has a 1 year low of $1.51 and a 1 year high of $2.99.

Analysts Set New Price Targets

NSPR has been the subject of several research reports. Lake Street Capital reissued a “buy” rating on shares of InspireMD in a research report on Tuesday, February 24th. Loop Capital set a $5.00 target price on shares of InspireMD in a research report on Tuesday, February 24th. Finally, Maxim Group assumed coverage on shares of InspireMD in a research note on Monday, February 2nd. They set a “buy” rating and a $6.00 target price for the company. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $5.00.

Insiders Place Their Bets

In other InspireMD news, insider Shane Thomas Gleason sold 17,593 shares of the business’s stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $1.62, for a total value of $28,500.66. Following the sale, the insider owned 1,174,664 shares of the company’s stock, valued at $1,902,955.68. The trade was a 1.48% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold a total of 61,194 shares of company stock worth $99,188 in the last 90 days. 34.06% of the stock is owned by insiders.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.